- An experimental once-daily GLP-1 pill called aleniglipron helped people with obesity or overweight lose up to 12.1% of body weight in 36 weeks.
- Unlike injectable GLP-1 medicines, aleniglipron is a small-molecule tablet that can be taken with or without food.
- The phase 2 results are promising, but larger phase 3 trials are still needed before it can be judged properly.
A new oral GLP-1 medicine has shown strong weight loss results in a phase 2 trial.
The drug, called aleniglipron, is being developed as a once-daily tablet for people with obesity or overweight.
After 36 weeks, people taking the highest dose lost an average of 12.1% of their body weight.
That compares with just 0.5% in the placebo group.
Lower doses also led to meaningful weight loss, with average reductions of 9.0% and 10.7%.
The trial included 230 adults across 38 medical centres in the United States.
- GLP-1 weight loss drugs may be misused by people with eating disorders
- First GLP-1 pill for weight loss approved in the UK
Participants were randomly assigned to receive either placebo or aleniglipron at doses of 45mg, 90mg or 120mg.
The dose was increased every four weeks during treatment.
The drug works through the GLP-1 pathway, the same broad hormone system targeted by medicines such as semaglutide.
GLP-1 medicines help stimulate insulin release, reduce appetite and increase fullness.
That combination can support weight loss and improve blood glucose control.
What makes aleniglipron different is its structure.
Current GLP-1 drugs such as Wegovy and Ozempic are peptide-based medicines, usually given by injection.
Aleniglipron is a small molecule.
That means it is chemically made, taken by mouth and potentially easier to manufacture at scale.
It can also be taken with or without food, which could make it easier to use than some oral medicines that require careful timing around meals.
Side effects were mainly gastrointestinal, as expected with this drug class.
Most were mild to moderate and became less common as the study went on.
Around 10% of participants stopped treatment, and researchers reported no cases of drug-induced liver injury.
That is reassuring, but this is still early.
- Oral GLP-1 drugs may turn down the brain’s food craving circuit
- UK heatwave: people taking GLP-1 weight loss drugs warned to watch for dehydration
Phase 2 trials are designed to explore dose, safety and signal of effect.
They are not the final test.
The real question is whether aleniglipron can perform well in larger, longer phase 3 trials and whether people can stay on it in real-world use.
For people with obesity, type 2 diabetes or both, oral GLP-1 medicines could become important.
They may reduce barriers linked to injections, storage and supply.
But convenience will not be enough on its own.
The drug still needs to prove long-term safety, durability and meaningful health benefit beyond weight loss.
